Literature DB >> 21675880

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

Marc R Theoret1, Yang-Min Ning, Jenny J Zhang, Robert Justice, Patricia Keegan, Richard Pazdur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21675880     DOI： 10.1056/NEJMp1106783

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  55 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 2.  Chemoprevention of prostate cancer: an updated view.

Authors:  Eric A Klein; Ian M Thompson
Journal:  World J Urol       Date:  2012-01-12       Impact factor: 4.226

3.  Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Authors:  Laurence Klotz; Michael Chetner; Joseph Chin; Tony Finelli; Neil Fleshner; Yves Fradet; Larry Goldenberg; J Curtis Nickel; Robert Siemens; Alan So; Linda Sugar; Alexandre Zlotta; Eric Klein; Howard Parnes; David Penson
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

4.  A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

Authors:  Ji-An Liang; Li-Min Sun; Ming-Chia Lin; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo; Chia-Hung Kao
Journal:  Oncologist       Date:  2012-06-20

Review 5.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

6.  Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Authors:  Reith R Sarkar; J Kellog Parsons; Alex K Bryant; Stephen T Ryan; Andrew K Kader; Rana R McKay; Anthony V D'Amico; Paul L Nguyen; Benjamin J Hulley; John P Einck; Arno J Mundt; Christopher J Kane; James D Murphy; Brent S Rose
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

7.  Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.

Authors:  Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

8.  The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Authors:  Neerav Monga; Amyn Sayani; Daniel A Rubinger; Timothy H Wilson; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

Review 9.  Prostate Cancer Prevention: Concepts and Clinical Trials.

Authors:  Zachary Hamilton; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

10.  20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.

Authors:  Bo Cao; Xichun Liu; Jing Li; Shuang Liu; Yanfeng Qi; Zhenggang Xiong; Allen Zhang; Thomas Wiese; Xueqi Fu; Jingkai Gu; Paul S Rennie; Oliver Sartor; Benjamin R Lee; Clement Ip; Lijuan Zhao; Haitao Zhang; Yan Dong
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.